AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29402509 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RES)
Number of subjects: 30
Study 27595918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (weight loss)
Number of subjects: 5145
Study 27595918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (fitness change)
Number of subjects: 5145
Study 24460536 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based intervention including targeted education on myopia, structured weekend outdoor activities, and incentives for increasing daily steps via pedometers.
Number of subjects: 285
Study 24460536 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based intervention
Number of subjects: 285
Study 24460536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study 23278322 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflubenzuron, Eprinomectin, Fipronil, Ivermectin (feed-through treatments)
Number of subjects: 2
Study 23278322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fipronil (250 p.p.m., 100 p.p.m., 50 p.p.m.)
Number of subjects: 2
Study 19888949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 15 mg/kg, maximum 1000 mg over 15 minutes
Number of subjects: 559
Study 19888949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559
Study 19888949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 559
Study 18071002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3187
Study 18071002 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle (ILS)
Number of subjects: 3187
Study 18071002 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 3187
Study 15679783 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (control group)
Number of subjects: 101
Study 15679783 — intervention group
Group type: EXPERIMENTAL
Intervention: Very heavy smokers (>30 cigarettes/day)
Number of subjects: 101
Study 12852706 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide/metformin 5/500 mg tablets
Number of subjects: 247
Study 12852706 — intervention group
Group type: COMPARATOR
Intervention: Glipizide 30 mg
Number of subjects: 247
Study 12852706 — intervention group
Group type: COMPARATOR
Intervention: Metformin 2000 mg
Number of subjects: 247
Study 10587555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosing injections (dextrose-glycerine-phenol with lignocaine)
Number of subjects: 74
Study 10587555 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (saline plus lignocaine)
Number of subjects: 74
Study 8945675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide-5-mononitrate
Number of subjects: 20
Study 8945675 — intervention group
Group type: COMPARATOR
Intervention: Continuous transdermal nitroglycerin
Number of subjects: 20
Study 8945675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 1769431 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 10
Study 1769431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7329878 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available medium pressure mercury sun lamps
Number of subjects: 0
Study 7329878 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31564513 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and Amlodipine 10 mg co-administration
Number of subjects: 27
Study 31564513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg alone
Number of subjects: 27
Study 31564513 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of all 3 drugs
Number of subjects: 27
Study 28142075 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day rosuvastatin (n = 24)
Number of subjects: 45
Study 28142075 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin (n = 21)
Number of subjects: 45
Study 28142075 — intervention group
Group type: COMPARATOR
Intervention: Control group (LDL‐C <3.37 mmol/L)
Number of subjects: 45
Study 27464953 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Rehabilitation Program (MRP) consisting of graded exposure module or a combination module of graded exposure and physical training, with a parent module added. Treatment duration varies between 7 and 16 weeks.
Number of subjects: 124
Study 27464953 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 124
Study 25124237 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine (three doses)
Number of subjects: 171
Study 25124237 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 171
Study 22595153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 0
Study 22595153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19678773 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture + 10 mg/day fluoxetine + placebo
Number of subjects: 80
Study 19678773 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture + 20‐30 mg/day fluoxetine
Number of subjects: 80
Study 19678773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 18189060 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0
Study 18189060 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 18189060 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 18189060 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 0
Study 15323595 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 71
Study 15323595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum folate levels
Number of subjects: 71
Study 15323595 — intervention group
Group type: COMPARATOR
Intervention: Low vitamin B12 levels
Number of subjects: 71
Study 15323595 — intervention group
Group type: COMPARATOR
Intervention: Elevated homocysteine levels
Number of subjects: 71
Study 11431189 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (200 to 300 mg after each hemodialysis session)
Number of subjects: 16
Study 11431189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9875115 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBI‐SPECT
Number of subjects: 102
Study 9875115 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress testing
Number of subjects: 102
Study 9875115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole echocardiography
Number of subjects: 102
Study 9875115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography
Number of subjects: 102
Study 9875115 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic techniques
Number of subjects: 102
Study 7722589 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (offered the opportunity to execute an Advance Directive)
Number of subjects: 204
Study 7722589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Advance Directive offered)
Number of subjects: 204
Study 2783939 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (3 million IU to 36 million IU intramuscularly daily for 10 weeks)
Number of subjects: 22
Study 1097480 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline 10 mg three times a day
Number of subjects: 0
Study 1097480 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine 2 mg three times a day
Number of subjects: 0
Study 1097480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of protriptyline and perphenazine
Number of subjects: 0
Study 1097480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31745040 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond multi‐purpose (MP)
Number of subjects: 125
Study 31745040 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bond plus (SB)
Number of subjects: 125
Study 31745040 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond SE (SE)
Number of subjects: 125
Study 31745040 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy bond (EB)
Number of subjects: 125
Study 28592577 — intervention group
Group type: EXPERIMENTAL
Intervention: ASyMS intervention
Number of subjects: 1108
Study 28592577 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1108
Study 25737169 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (lansoprazole, amoxicillin, and clarithromycin for 14 days)
Number of subjects: 61
Study 25737169 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus probiotics (Lactobacillus casei, Lactobacillus acidophilus, and Bifidobacterium lactis)
Number of subjects: 61
Study 23758279 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based model of care led by a general practitioner with advanced skills and an endocrinologist partnership.
Number of subjects: 330
Study 23758279 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided via the hospital diabetes outpatient department.
Number of subjects: 330
Study 21477426 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray (1 spray/nostril twice-daily)
Number of subjects: 944
Study 21477426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 spray/nostril twice-daily)
Number of subjects: 944
Study 18809153 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/day
Number of subjects: 1075
Study 18809153 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin 80 mg/day
Number of subjects: 1075
Study 18809153 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1075
Study 15695784 — intervention group
Group type: EXPERIMENTAL
Intervention: FMISO PET imaging
Number of subjects: 40
Study 14626291 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20 (Synvisc®)
Number of subjects: 0
Study 10795662 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 20
Study 10795662 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 20
Study 8641640 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyowa ASP
Number of subjects: 40
Study 8641640 — intervention group
Group type: COMPARATOR
Intervention: Bayer ASP
Number of subjects: 40
Study 1628635 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% halothane in pure oxygen
Number of subjects: 0
Study 1628635 — intervention group
Group type: COMPARATOR
Intervention: 0.5% halothane in 50% oxygen/50% nitrous oxide
Number of subjects: 0
Study 6705617 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational skills training (individual coaching)
Number of subjects: 56
Study 6705617 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer involvement under superordinate goals (group experience)
Number of subjects: 56
Study 6705617 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational skills training combined with peer involvement (group experience with coaching)
Number of subjects: 56
Study 6705617 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 56
Study 31036503 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention (diet, exercise, or diet plus exercise)
Number of subjects: 577
Study 29315212 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake
Number of subjects: 310
Study 27349698 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (higher-dose edoxaban regimen; 60 mg dose-reduced to 30 mg once daily)
Number of subjects: 14071
Study 27349698 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14071
Study 24940704 — intervention group
Group type: EXPERIMENTAL
Intervention: Knifelight carpal tunnel release
Number of subjects: 82
Study 24940704 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 82
Study 22805873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic treatment (H)
Number of subjects: 50
Study 22805873 — intervention group
Group type: COMPARATOR
Intervention: Normothermic treatment (N)
Number of subjects: 50
Study 20391147 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction and/or resistance training
Number of subjects: 36
Study 17907238 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity aerobic training
Number of subjects: 80
Study 17907238 — intervention group
Group type: COMPARATOR
Intervention: Qigong (control group)
Number of subjects: 80
Study 12569112 — intervention group
Group type: EXPERIMENTAL
Intervention: Konjac glucomannan (KGM) supplement (3.6 g/day) for 28 days
Number of subjects: 22
Study 10848657 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d.
Number of subjects: 156
Study 10848657 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg b.d.
Number of subjects: 156
Study 9139554 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of fluconazole per week
Number of subjects: 323
Study 9139554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 8229393 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid solution (4.8%) used as a mouthwash
Number of subjects: 93
Study 8229393 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 93
Study 3100353 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 200 mg 4 times a day
Number of subjects: 33
Study 3100353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30042362 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek mountain tea 950 mg
Number of subjects: 155
Study 30042362 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek mountain tea 475 mg
Number of subjects: 155
Study 30042362 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek mountain tea 475 mg and 950 mg
Number of subjects: 155
Study 30042362 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba 240 mg
Number of subjects: 155
Study 30042362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 26760452 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled SMS reminders (daily for 1 month, weekly for 2 months)
Number of subjects: 63
Study 26760452 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered SMS reminders starting at enrolment
Number of subjects: 63
Study 26760452 — intervention group
Group type: COMPARATOR
Intervention: Control (No SMS)
Number of subjects: 63
Study 24951991 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated fish oil (3 g/day containing 0.41 g/day of eicosapentaenoic acid and decosahexaneoic acid)
Number of subjects: 30
Study 24951991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24951991 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated fish oil
Number of subjects: 30
Study 22313884 — intervention group
Group type: EXPERIMENTAL
Intervention: External methods of traditional Chinese medicine (TCM)
Number of subjects: 0
Study 20210614 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) clothing comprising shorts, socks, and sneakers
Number of subjects: 10
Study 20210614 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial (PART) National Football League (NFL) uniform comprising the uniform without helmet or shoulder pads
Number of subjects: 10
Study 20210614 — intervention group
Group type: EXPERIMENTAL
Intervention: Full (FULL) NFL uniform
Number of subjects: 10
Study 20210614 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial (PART) National Football League (NFL) uniform
Number of subjects: 10
Study 18717873 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% doxepin hydrochloride cream
Number of subjects: 10
Study 18717873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16404688 — intervention group
Group type: EXPERIMENTAL
Intervention: International therapeutic modernity and ethical rules governing experiments
Number of subjects: 0
Study 16404688 — intervention group
Group type: EXPERIMENTAL
Intervention: New laws on international trade
Number of subjects: 0
Study 12798825 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (metoprolol, bisoprolol, carvedilol)
Number of subjects: 0
Study 12798825 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (CIBIS II trial)
Number of subjects: 0
Study 10230185 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic agents
Number of subjects: 0
Study 10230185 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 10230185 — intervention group
Group type: COMPARATOR
Intervention: Combination of atypical antipsychotics and psychosocial interventions
Number of subjects: 0
Study 8781015 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1677656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 191
Study 1677656 — intervention group
Group type: COMPARATOR
Intervention: Cephradine
Number of subjects: 191
Study 6310997 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdinocillin plus a beta-lactam antibiotic
Number of subjects: 78
Study 6310997 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside plus a beta-lactam antibiotic
Number of subjects: 78
Study 6310997 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside
Number of subjects: 78
Study 6310997 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdinocillin
Number of subjects: 78
Study 31476969 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort provided by parents
Number of subjects: 38
Study 31476969 — intervention group
Group type: COMPARATOR
Intervention: Comfort provided by strangers
Number of subjects: 38
Study 31277073 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted panel sequencing (TPS)
Number of subjects: 125
Study 31277073 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 125
Study 27350625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (160 mg once daily) with Metformin (500 mg twice daily)
Number of subjects: 111
Study 27350625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (100 mg once daily) with Warfarin (25 mg)
Number of subjects: 111
Study 27350625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (100 mg once daily) with Digoxin (0.25 mg)
Number of subjects: 111
Study 27350625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (100 mg once daily) with COC (30/150 µg once daily)
Number of subjects: 111
Study 27350625 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron (100 mg once daily)
Number of subjects: 111
Study 26496210 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg of paricalcitol
Number of subjects: 36
Study 26496210 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated groups (1 or 2 μg of paricalcitol)
Number of subjects: 36
Study 26496210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24341367 — intervention group
Group type: EXPERIMENTAL
Intervention: FL‐PDT (Fractional laser-assisted photodynamic therapy)
Number of subjects: 40
Study 24341367 — intervention group
Group type: EXPERIMENTAL
Intervention: FL‐PDT
Number of subjects: 40
Study 24341367 — intervention group
Group type: COMPARATOR
Intervention: MAL‐PDT (Methyl aminolevulinate photodynamic therapy)
Number of subjects: 40
Study 24341367 — intervention group
Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 40
Study 22840639 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural change intervention (goal-setting, feedback, self-monitoring) delivered through individualised consultation calls and motivational SMS text messages over six months.
Number of subjects: 156
Study 22840639 — intervention group
Group type: COMPARATOR
Intervention: Usual care (advice from doctors about physical activity).
Number of subjects: 156
Study 19615128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential non-invasive mechanical ventilation following short-term invasive mechanical ventilation
Number of subjects: 32
Study 17719333 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1326
Study 17719333 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1326
Study 15533256 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of a flyer and letter with a health questionnaire informing patients that returned questionnaires would be entered into a lottery-style draw for £100 of gift vouchers.
Number of subjects: 8645
Study 15533256 — intervention group
Group type: COMPARATOR
Intervention: Health questionnaire accompanied only by standard letter of explanation.
Number of subjects: 8645
Study 11489325 — intervention group
Group type: EXPERIMENTAL
Intervention: Double matrix systems (starch-based hot stage extruded)
Number of subjects: 9
Study 11489325 — intervention group
Group type: COMPARATOR
Intervention: Reference immediate release formulation
Number of subjects: 9
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg (Group A1)
Number of subjects: 142
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Morphine 2 mg (Group A2)
Number of subjects: 142
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg (Group A3)
Number of subjects: 142
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Morphine 5 mg (Group A4)
Number of subjects: 142
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 ml (Group A5)
Number of subjects: 142
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 ml + Morphine 2 mg (Group A6)
Number of subjects: 142
Study 9430568 — intervention group
Group type: COMPARATOR
Intervention: Saline solution 20 ml (Group A7)
Number of subjects: 142
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg (Group B2)
Number of subjects: 142
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Morphine 5 mg (Group B3)
Number of subjects: 142
Study 9430568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 ml + Morphine 2 mg (Group B5)
Number of subjects: 142